Jin Rong Jie·2025-07-30 03:58Core Viewpoint - Fosun Pharma (02196) shares increased by over 4%, reaching HKD 20.15 with a trading volume of HKD 201 million, following the announcement of a licensing agreement with NewCo for the development of AR1001 for Alzheimer's disease and other neurological disorders [1] Group 1: Licensing Agreement - Fosun Pharma's subsidiary signed a licensing agreement with NewCo, granting rights for the development, registration, production, and commercialization of AR1001 in designated regions (Mainland China and Hong Kong/Macau) for Alzheimer's disease and other neurological conditions [1] - Fosun Pharma will pay up to RMB 150 million to NewCo for this licensing agreement [1] Group 2: Clinical Trials - The drug AR1001 was licensed from AriBioCO., Ltd. by NewCo, which is conducting global Phase III clinical trials targeting early Alzheimer's disease patients [1] - The global trial has completed recruitment in 13 countries and regions, including North America, Europe, the UK, China, and South Korea, with approximately 1,500 patients enrolled [1]